Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Tables)

v3.23.1
Note 3 - Revenue (Tables)
3 Months Ended
Mar. 31, 2023
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended March 31,

 
   

2023

   

2022

 

Seagen

  $ 1,423     $ 312  

AstraZeneca

    434       4,753  

Servier

    (74 )     4,734  

Genentech

    153       1,189  

Total Revenue

  $ 1,936     $ 10,988  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

AstraZeneca

  $ 504     $ 3,750  

Servier

    20        

Seagen

    759       450  

Boston Pharmaceuticals

    88       265  

Genentech

    626       450  

Total potential milestone payments

  $ 1,997     $ 4,915